Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04649229 · ClinicalTrials.gov registry record · Phase 4
Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3
A Phase 4 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 4
- Development phase
- 46
- Enrollment target
NCT04649229 is a Phase 4 study that has completed, run by Yale University. The registered enrollment target is 46 participants.
The verdict
NCT04649229, a Phase 4 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 46 participants
- Enrollment target
Study Summary
This is a double-blind, randomized, two x two crossover (aprepitant vs placebo) during both initiation of Entresto, LCZ696, (50 mg dose) and at steady-state of Entresto (200 mg bid dose or the highest tolerated dose).
Interventions
- DRUG Placebo
- DRUG Iohexol
- DRUG Aprepitant
- DRUG LCZ 696
- DRUG Para-aminohippurate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 46 participants |
| Start Date | 2021-05-27 |
| Est. Completion | 2025-05-22 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04649229
The ClinicalTrials.gov registry entry for NCT04649229 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 46 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT04649229 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04649229 about?
NCT04649229 is a clinical study titled "Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 3". This is a double-blind, randomized, two x two crossover (aprepitant vs placebo) during both initiation of Entresto, LCZ696, (50 mg dose) and at steady-state of Entresto (200 mg bid dose or the highest tolerated dose).
What is the current status of trial NCT04649229?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 46 participants. The study started on 2021-05-27. Estimated completion is 2025-05-22.
What interventions are being tested in trial NCT04649229?
The interventions under investigation include: Placebo (DRUG), Iohexol (DRUG), Aprepitant (DRUG), LCZ 696 (DRUG), Para-aminohippurate (DRUG).
Who is sponsoring clinical trial NCT04649229?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.